Financial Data and Key Metrics Changes - Total revenues for Q3 2025 were $8.6 million, down from $12.8 million in Q3 2024, primarily due to variability in customers' manufacturing schedules and clinical trial progression [15] - Product gross margin increased to 64% in Q3 2025 from 61% in Q3 2024, attributed to a shift towards more profitable products [16] - Net loss for Q3 2025 was $19.6 million, or $0.22 per share, compared to a net loss of $20.6 million, or $0.29 per share, in Q3 2024 [17] Business Line Data and Key Metrics Changes - The company has transitioned from one revenue-bearing contract to 11, with 40 more in the pipeline, indicating strong commercial traction for the Eco-synthesis platform [4][5] - The historical small molecule biocatalysis business is expected to experience a decline in service revenue next year, but this will be offset by development services in the ligase and Eco-synthesis areas [12] Market Data and Key Metrics Changes - The company is moving away from promoting its historical small molecule biocatalysis business due to pricing pressures and is refocusing on the ligase and Eco-synthesis business lines [12] - There are 14 drugs using the company's enzymes in phase three clinical trials, with data readouts expected in the next 12 months, which could fuel growth in the existing pipeline [13] Company Strategy and Development Direction - The company aims to transform into a full-service manufacturing innovator in oligonucleotide manufacturing, with plans to build a GMP facility for siRNA production [4][5] - The leadership transition is designed to streamline operations and focus on Eco-synthesis, enhancing the company's ability to deliver production technologies to customers [6][9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the market potential for the Eco-synthesis platform and the importance of optimizing the organization for future success [5][6] - The restructuring is expected to reduce the company's burn rate by approximately 25%, extending its financial runway through 2027 [15] Other Important Information - The company signed a supply assurance agreement with Merck, providing a vital infusion of non-dilutive cash to support business plans [11] - The company is preparing for presentations at Tides Europe, focusing on technology scaling and in-process analytics, which are expected to be impactful for commercial progress [34] Q&A Session Summary Question: Impact of leadership transition on partnership strategy - Management confirmed that the transition will not change their plans and they are encouraged by the progress made in securing early-phase contracts [20] Question: Unique capabilities of Nitto Avecia - Management highlighted Nitto Avecia's expertise in scaling technology for larger batch sizes, which is crucial for phase two, phase three, and commercial production [28] Question: Contribution of siRNA revenue to product revenue segment - Current contracts are in the service area, and while service revenue is expected to remain consistent, the source of that revenue is shifting [32] Question: Expectations for Tides Europe presentations - The company plans to showcase data on technology scaling and in-process control, which are anticipated to be first-in-class presentations for siRNA therapeutic developers [34]

Revenue Performance - Total revenues decreased by $4.2 million to $8.6 million in the three months ended September 30, 2025, a decline of 33% compared to the same period in 2024[96]. - Product revenue fell by $4.4 million to $6.8 million in the three months ended September 30, 2025, representing a 39% decrease year-over-year[97]. - Research and development revenue increased by $0.1 million to $1.8 million in the three months ended September 30, 2025, a 7% increase compared to the same period in 2024[98]. - Product revenue for the three months ended September 30, 2025, was $6,807,000, a decrease of $4,351,000 or 39% compared to $11,158,000 in 2024[101]. Expenses and Losses - Total costs and operating expenses decreased by $1.8 million to $27.6 million in the three months ended September 30, 2025, a 6% reduction compared to the same period in 2024[100]. - Loss from operations increased by $2.4 million to $18.9 million in the three months ended September 30, 2025, a 14% increase compared to the same period in 2024[92]. - Research and development expenses increased by $2.4 million in the three months ended September 30, 2025, primarily due to higher employee-related costs and lab supplies[103]. - Selling, general and administrative expenses decreased by $2.4 million during the three months ended September 30, 2025, mainly due to lower consulting and outside services[105]. - Net loss for the three months ended September 30, 2025, was $19.6 million, a slight improvement from a net loss of $20.6 million in the same period in 2024[113]. Cash Flow and Financing - Cash and cash equivalents increased to $25,351,000 as of September 30, 2025, compared to $19,264,000 at December 31, 2024[116]. - The company borrowed an additional $10.0 million on June 27, 2025, under a loan agreement, bringing the total borrowed to $40.0 million[115]. - Net cash used in operating activities increased by $6.5 million to $(39,468) thousand for the nine months ended September 30, 2025, compared to $(32,942) thousand in 2024[125]. - Net cash provided by investing activities increased by $71.9 million to $17,789 thousand for the nine months ended September 30, 2025, compared to $(54,117) thousand in 2024[126]. - Net cash provided by financing activities decreased by $31.6 million to $27,748 thousand for the nine months ended September 30, 2025, compared to $59,390 thousand in 2024[127]. - As of September 30, 2025, unrestricted cash, cash equivalents, and short-term investments totaled $58.7 million[131]. Interest Income and Other Income - Interest income decreased by $0.2 million to $0.6 million in the three months ended September 30, 2025, a 25% decline year-over-year[92]. - Interest income decreased by $0.2 million and $0.8 million in the three and nine months ended September 30, 2025, respectively, due to lower average cash balances[109]. - Total other income (expense), net for the three months ended September 30, 2025, was $(4,073,000), a decrease of $1,248,000 or 84% compared to the same period in 2024[107]. Future Outlook and Risks - The company expects that existing cash and cash equivalents, along with future product revenues, will provide adequate funds for operations for at least the next 12 months[122]. - The company may require additional capital for product development and commercialization, depending on various factors including financial success and market opportunities[123]. - The company is exposed to foreign currency risk, particularly from non-functional currency denominated monetary assets, which may affect operational results[133]. - A hypothetical 10% decrease in market interest rates would result in a $0.3 million impact on future interest income and cash flows[131]. Research and Development Initiatives - The ECO Synthesis Innovation Lab was completed at the end of 2024, enabling the synthesis of gram-scale quantities of siRNA constructs for pre-clinical testing[90]. - In 2025, the company expects to manufacture GLP-grade siRNA for customers and anticipates entering a partnership with a large-scale CDMO for GMP-grade siRNA production[90]. - The company reported a 19% increase in research and development expenses to $40.6 million for the nine months ended September 30, 2025, compared to $34.2 million in the same period in 2024[100]. - Product gross margin improved to 64% for both the three and nine months ended September 30, 2025, compared to 61% and 53% in the corresponding periods in 2024[101].

Business Highlights - Codexis secured a $37.8 million Supply Assurance Agreement with Merck [7, 15] - The company expects to receive the cash from the Merck agreement by the end of 2025 [7, 15] - Codexis has a cash runway through 2027 [7] - Codexis has 11 customers this year and a pipeline of 40 prospects [7, 13] - The company will sign a lease on a 34,000 square feet multi-purpose GMP facility in the next few weeks [7] Executive Management Transition and Cost Reduction - Codexis is reducing operating expenses by 25% through the elimination of 46 positions [10] - Dr Stephen Dilly will transition to Chairman, and Dr Alison Moore will assume the role of President and CEO [10] Q3 2025 Financial Results - Total revenue for Q3 2025 was $8.6 million, compared to $12.8 million in Q3 2024 [16] - Product gross margin increased to 64% in Q3 2025 from 61% in Q3 2024 [16] - R&D expenses for Q3 2025 were $13.9 million, compared to $11.5 million in Q3 2024 [16] - Net loss for Q3 2025 was $19.6 million, or $0.22 per share, compared to a net loss of $20.6 million, or $0.29 per share, in Q3 2024 [16]

Financial Performance - Total revenues for Q3 2025 were $8.6 million, a decrease of 32.8% from $12.8 million in Q3 2024[6] - Net loss for Q3 2025 was $19.6 million, or $0.22 per share, compared to a net loss of $20.6 million, or $0.29 per share, in Q3 2024[11] Product and Operational Metrics - Product gross margin improved to 64% in Q3 2025, up from 61% in Q3 2024, due to a shift towards more profitable products[6] - Research and Development expenses increased to $13.9 million in Q3 2025, compared to $11.5 million in Q3 2024, driven by higher headcount and lab supplies[6] Workforce and Management Changes - Codexis eliminated 46 positions, approximately 24% of its workforce, expecting an additional expense of about $3.5 million in Q4 2025[6] - Alison Moore has been appointed as the new CEO, succeeding Stephen Dilly, who will become Chairman of the Board[6] Cash and Investments - As of September 30, 2025, Codexis had $58.7 million in cash, cash equivalents, and short-term investments[11] - Cash and cash equivalents increased from $19,264 million to $25,351 million, an increase of about 31.5%[19] Assets and Liabilities - Total assets decreased from $149,011 million in December 2024 to $123,961 million in September 2025, a decline of approximately 16.8%[19] - Current assets fell from $98,772 million to $76,192 million, representing a decrease of about 22.9%[19] - Total liabilities increased from $82,084 million to $85,417 million, an increase of approximately 4.0%[19] - Long-term debt rose significantly from $28,905 million to $39,729 million, marking an increase of about 37.5%[19] - Stockholders' equity decreased from $66,927 million to $38,544 million, a decline of approximately 42.4%[19] - Total current liabilities decreased from $23,648 million to $18,475 million, a decline of about 21.9%[19] Accounts and Inventories - Accounts receivable decreased from $11,920 million to $6,030 million, a decline of approximately 49.5%[19] - Inventories increased from $1,799 million to $1,936 million, representing an increase of about 7.6%[19] Strategic Agreements and Future Plans - The company signed a $37.8 million Supply Assurance Agreement with Merck, with cash expected to be received by year-end 2025[6] - The company is transitioning to an innovative manufacturing solutions provider in oligonucleotide manufacturing, with a focus on ECO Synthesis technology[2] - Codexis will present at the 2025 TIDES Europe Annual Meeting from November 11-13 in Basel, Switzerland[4] Accumulated Deficit - Accumulated deficit increased from $562,806 million to $616,381 million, a rise of approximately 9.5%[19]

Core Insights - Codexis, Inc. has signed a $37.8 million Supply Assurance Agreement with Merck, which is expected to provide a significant non-dilutive cash infusion into the company [2][3][6] - Organizational changes have been implemented to streamline operations and reduce expenses, including a leadership transition where Dr. Alison Moore will succeed Dr. Stephen Dilly as CEO [3][6] - The company has extended its cash runway through 2027, allowing for continued investment in its innovative manufacturing solutions [2][3] Financial Performance - Total revenues for the third quarter of 2025 were $8.6 million, a decrease from $12.8 million in the same quarter of 2024, primarily due to variability in customers' manufacturing schedules and clinical trial progression [12][15] - Product gross margin improved to 64% in Q3 2025 from 61% in Q3 2024, attributed to a shift towards more profitable products [12] - The net loss for Q3 2025 was $19.6 million, or $0.22 per share, compared to a net loss of $20.6 million, or $0.29 per share, in Q3 2024 [12][16] Organizational Changes - Dr. Stephen Dilly will transition to Chairman of the Board, while Dr. Alison Moore, previously Chief Technology Officer, will take over as CEO [3][6] - The company has eliminated 46 positions, approximately 24% of its workforce, to reduce operational costs [6] - Dr. Stefan Lutz has been promoted to Chief Scientific Officer, and Georgia Erbez will also serve as Chief Business Officer [6] Upcoming Events - Codexis will present at the 2025 TIDES Europe Annual Meeting from November 11-13 in Basel, Switzerland [5]

Core Insights - Codexis, Inc. and Nitto Denko Avecia, Inc. have entered into an evaluation agreement to explore Codexis' ECO Synthesis® Manufacturing Platform, which aims to enhance oligonucleotide therapeutics manufacturing [1][2][3] Company Overview - Codexis is a leader in enzymatic solutions for therapeutic manufacturing, focusing on high-quality and efficient production methods that surpass traditional techniques [4] - Nitto Denko Avecia specializes in contract development and manufacturing of oligonucleotide therapeutics, with a strong portfolio and extensive experience in the field [4] Collaboration Details - The agreement will facilitate licensing discussions and promote broader adoption of the ECO Synthesis platform, which utilizes an enzyme-catalyzed approach for scalable manufacturing [2][3] - This partnership is seen as a significant milestone for both companies, aiming to redefine scalability and sustainability in therapeutic development [3] Strategic Goals - The collaboration aligns with Nitto Denko Avecia's mission to innovate in oligonucleotide manufacturing and deliver high-quality therapeutics globally [3] - Codexis aims to expand the reach of its ECO Synthesis platform through strategic partnerships with leading CDMOs [3]

Core Viewpoint - Codexis, Inc. will report its financial results for Q3 2025 on November 6, 2025, and will host a conference call to discuss these results and provide a business update [1]. Company Overview - Codexis is a leading provider of enzymatic solutions aimed at efficient and scalable manufacturing of complex therapeutics, utilizing its proprietary CodeEvolver technology platform [3]. - The company is developing the ECO Synthesis™ manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route [3]. - Codexis' enzymes are designed to address challenges in small molecule pharmaceuticals manufacturing and nucleic acid synthesis, offering benefits such as higher yields, reduced energy usage, and improved efficiency [3].

Core Insights - Codexis (NASDAQ: CDXS) is transitioning from selling enzyme parts to becoming an integrated supplier of siRNA through their ECO synthesis technology, which aims to enhance the efficiency of pharmaceutical research and production [1] Group 1: Company Overview - Codexis specializes in enzymatic solutions that improve pharmaceutical research and production efficiency [1] Group 2: Technological Development - The company is evolving its business model to include integrated siRNA supply alongside its existing enzyme offerings, leveraging its ECO synthesis technology [1]

Summary of Codexis Conference Call Company Overview - Codexis specializes in protein engineering and biocatalysis, providing solutions for small molecule medicines like Januvia and Paxlovid [4][4] - The company is now focusing on enzymatic synthesis of oligonucleotides, particularly in the siRNA therapeutics space [4][4] Industry Insights - The siRNA therapeutics market is expected to grow significantly, with demand projected to increase from 100 kilos in 2023 to at least 10 metric tons by the end of the decade [8][8] - Recent announcements from companies like Novartis and CureVac indicate a growing demand, with CureVac projecting a need for 25 metric tons per year, which exceeds current phosphoramidite chemistry capabilities [9][9] - Codexis estimates that the demand could reach 50 metric tons or more as the market expands into preventive medicines and larger indications [9][9] Technical Challenges and Solutions - Current chemical synthesis methods for siRNA are inefficient, expensive, and labor-intensive, requiring significant raw materials and infrastructure [6][6] - Codexis offers a range of solutions from ligation of shortmers to end-to-end enzymatic synthesis, which can improve yield and reduce costs [10][10][12][12] - The company is engaged with multiple customers, including one drug moving into phase 3 trials, demonstrating the feasibility and scalability of their platform [11][11] Customer Engagement and Market Strategy - Codexis has seen a significant increase in customer engagement, with a progression from one contract in 2024 to multiple contracts signed in 2023 [21][21] - The company aims to partner with biotech firms that have strong management teams, funding, and potential for large indications [21][21] - Codexis is focused on long-term partnerships, with revenue growth expected as customers move through clinical development stages [28][28][30][30] Competitive Landscape - Codexis positions itself against established companies like Novartis and Alnylam, which have existing supply chains for their drugs [26][26] - The company believes its enzymatic process offers a faster and more cost-effective solution for scaling production compared to traditional methods [26][26] Future Developments - Codexis plans to showcase its capabilities at upcoming conferences, including the ability to produce GMP drugs at required clinical trial quantities [39][39] - The company is also exploring advancements in chiral control for molecules, which could lead to more potent and safer therapeutics [40][40][41][41] Financial Position - As of the last quarter, Codexis reported over $60 million in cash, sufficient to establish its GMP facility and support future growth [42][42] Conclusion - Codexis is well-positioned in the growing siRNA therapeutics market, with innovative solutions to address current production challenges and a strong pipeline of potential partnerships and revenue growth opportunities [43][43]

Company Overview - Codexis, Inc. is a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics [3] - The company leverages its proprietary CodeEvolver® technology platform to discover, develop, and enhance novel, high-performance enzymes [3] - Codexis is developing its proprietary ECO Synthesis® manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route [3] Upcoming Events - Codexis will attend the Cantor Global Healthcare Conference from September 3-5, 2025, in New York, New York [1] - Management will participate in a fireside chat on September 4, 2025, at 3:55 pm ET, with a live webcast available on the company's Investor Relations website [2]